Cited by 914Psychedelics and Drug StudiesSmoking Behavior and CessationSubstance Abuse Treatment and Outcomes

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction

Open access

Johnson, Matthew W, Garcia-Romeu, Albert, Cosimano, Mary P, Griffiths, Roland R·2014·Journal of Psychopharmacology

DOI 10.1177/0269881114548296PMC PMC4286320

Open this paper in CoChat — free account

Abstract

Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an open-label pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment protocol. Participants were 15 psychiatrically healthy nicotine-dependent smokers (10 males; mean age of 51 years), with a mean of six previous lifetime quit attempts, and smoking a mean of 19 cigarettes per day for a mean of 31 years at intake. Biomarkers assessing smoking status, and self-report measures of smoking behavior demonstrated that 12 of 15 participants (80%) showed seven-day point prevalence abstinence at 6-month follow-up. The observed smoking cessation rate substantially exceeds rates commonly reported for other behavioral and/or pharmacological therapies (typically <35%). Although the open-label design does not allow for definitive conclusions regarding the efficacy of psilocybin, these findings suggest psilocybin may be a potentially efficacious adjunct to current smoking cessation treatment models. The present study illustrates a framework for future research on the efficacy and mechanisms of hallucinogen-facilitated treatment of addiction.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1177/0269881114548296

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire
HEATHERTON, T. F., KOZLOWSKI, L. T., FRECKER, R. C., & FAGERSTROM, K. (1991) · British Journal of Addiction · doi:10.1111/j.1360-0443.1991.tb01879.x · Cited by 10,738 · cited 1×
“The Fagerström Test for Cigarette Dependence (FTCD; formerly Fagerström Test for Nicotine Dependence) is a 6-item questionnaire widely used to characterize the level of dependence of cigarette smokers (Fagerström, 2012; Heatherton et al., 1991).”
Method
Untitled work
(2008) · Medical Entomology and Zoology · Cited by 7,477
The Health consequences of smoking—50 years of progress : a report of the Surgeon General
Lushniak, B. D., Samet, J. M., Pechacek, T. F., Norman, L., & Taylor, P. A. (2014) · Cited by 4,990
Timeline Follow-Back
Sobell, L. C., & Sobell, M. B. (1992) · Measuring Alcohol Consumption · doi:10.1007/978-1-4612-0357-5_3 · Cited by 4,110 · cited 1×
“The TLFB is a self-report calendar completed retrospectively by participants indicating the number of cigarettes smoked each day (Sobell and Sobell, 1992).”
Background
The Health Consequences of Smoking -- 50 Years of progress: A Report of the Surgeon General
General, U. S. S. (2014) · PsycEXTRA Dataset · doi:10.1037/e510072014-001 · Cited by 3,368
Biochemical verification of tobacco use and cessation
Benowitz, N. L., III, P. J., Ahijevych, K., Jarvis, M. J., Hall, S., LeHouezec, J., Hansson, A., Lichtenstein, E., Henningfield, J., Tsoh, J., et al. (2002) · Nicotine & Tobacco Research · doi:10.1080/14622200210123581 · Cited by 1,800 · cited 1×
“Two measures of recent smoking, exhaled carbon monoxide (CO) and urinary cotinine level (Benowitz et al., 2002), were assessed at intake, weekly throughout the intervention, and at 6-month follow-up.”
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 7×
“This 100- item questionnaire has previously been used to characterize the subjective effects of psilocybin (Griffiths et al., 2006, 2011).”
BackgroundMethodResultInfluentialSelf-citation
Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluential
Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · cited 3×
“For example, when paired with 12 brief weekly counseling meetings, pharmacotherapies have shown seven-day point prevalence abstinence rates of 24.9% to 26.3% (bupropion) and 33.5% to 35.2% (varenicline) at approximately 6 months post-TQD (Gonzales et al., 2006; Jorenby et al., 2006).”
BackgroundInfluential
The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs.
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252 · cited 1×
“Several plausible mechanisms of hallucinogen-facilitated treatments have been proposed (Bogenschutz and Pommy, 2012; Carhart-Harris et al., 2012, 2014; Ross, 2012; Vollenweider and Kometer, 2010).”
Background

Show all 63 references

Research works printed but not linked: 4

Griffiths RR, 1980, Adv Subst Abuse, 1, 1
Marks DF, 1993, The QUIT FOR LIFE Programme: An easier way to stop smoking and not start again
National Institute on Drug Abuse, 2005, LSD NIDA Infofacts
World Health Organization, 2011, WHO report on the global tobacco epidemic, 2011: Warning about the dangers of tobacco

Sorted by citations

Items 501–600 of 914

A pilot human study using ketamine to treat disorders of consciousness
Cardone, P., Bonhomme, A., Bonhomme, V. L., Lejeune, N., Staquet, C., Defresne, A., Alnagger, N., Ezan, P., Lee, M., Piarulli, A., et al. (2024) · iScience · doi:10.1016/j.isci.2024.111639 · Cited by 12
Psychedelic neuroplasticity of cortical neurons lacking 5-HT2A receptors
Ekins, T. G., Rybicki-Kler, C., Deng, T., Brooks, I. A. W., Jedrasiak‐Cape, I., Donoho, E., & Ahmed, O. J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03257-w · Cited by 13
Engineering New Branches of the Kynurenine Pathway To Produce Oxo-(2-aminophenyl) and Quinoline Scaffolds in Yeast
Torrens-Spence, M. P., Liu, C., & Weng, J. (2019) · ACS Synthetic Biology · doi:10.1021/acssynbio.9b00368 · Cited by 11
Psychedelics as Reemerging Treatments for Anxiety Disorders: Possibilities and Challenges in a Nascent Field
King, F., & Hammond, R. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20200047 · Cited by 14
Changed Substance Use After Psychedelic Experiences Among Individuals in Canada
Boehnke, K. F., Kruger, D. J., & Lucas, P. (2023) · International Journal of Mental Health and Addiction · doi:10.1007/s11469-023-01085-z · Cited by 17
“Johnson et al., 2014; M. W. Johnson et al., 2017).”
Molecular and structural insights into the 5‐HT 2C receptor as a therapeutic target for substance use disorders
Ubhayarathna, M., Langmead, C. J., Diepenhorst, N. A., & Stewart, G. D. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16233 · Cited by 12
“These findings were echoed in a nicotine addiction study; psilocybin treatment facilitated tobacco smoking cessation and was maintained after 12 months (Johnson et al., 2014, 2017).”
Microdosing psychedelics as cognitive and emotional enhancers.
Rifkin, B. D., Maraver, M. J., & Colzato, L. S. (2020) · Psychology of Consciousness Theory Research and Practice · doi:10.1037/cns0000213 · Cited by 15
Entheogenic Spirituality: Exploring Spiritually Motivated Entheogen Use among Modern Westerners.
Johnstad, P. G. (2018) · Journal of ethnographic and qualitative research · Cited by 12
Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics
Kojic, M., Saelens, J., Kadriu, B., Zarate, C. A., & Kraus, C. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_313 · Cited by 12
Exploring the effect of microdosing psychedelics on creativity in an open-label natural settingPreprint
Prochazkova, L., Lippelt, D. P., Colzato, L. S., Kuchař, M., Sjoerds, Z., & Hommel, B. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/384412 · Cited by 12
Psychiatry might need some psychedelic therapy
Johnson, M. W. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1509544 · Cited by 14
Self-citation
The psychological processes of classic psychedelics in the treatment of depression: a systematic review protocol
Johansen, L., Liknaitzky, P., Nedeljkovic, M., Mastin-Purcell, L., & Murray, G. (2022) · Systematic Reviews · doi:10.1186/s13643-022-01930-7 · Cited by 11
“Trials investigating the efficacy of psychedelicassisted psychotherapy to assist smoking cessation and alcohol dependence have also employed cognitive behavioural therapy [47] and motivational enhancement therapy [48], but these modalities are yet to be utilised in a depression sample.”
Background
Considerations and cautions for the integration of psilocybin into routine clinical care: a consensus statement from the US National Network of Depression Centers' Task Group on Psychedelics and Related Compounds
Hosein, M., Reid, M. J., Walser, S. A., Charney, S., Fonzo, G. A., Lewis, B. R., Yaden, D. B., Suppes, T. M., Cordner, Z. A., & Barrett, F. S. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103517 · Cited by 15
“Apart from MDD, psilocybin has also shown safety and potential utility in the treatment of AUD, 4,5 tobacco use disorder, 6,7 OCD, 26 migraine head-aches, 32 cluster headaches, 33 bipolar depression, 34 and anorexia nervosa.”
Experiences of Listening to Icaros during Ayahuasca Ceremonies at Centro Takiwasi:An Interpretive Phenomenological Analysis
Graham, O. J., Rojas, G. S., & Politi, M. (2022) · Anthropology of Consciousness · doi:10.1111/anoc.12170 · Cited by 11
Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic
Bălăeţ, M., Trender, W. R., Hellyer, P. J., & Hampshire, A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1184681 · Cited by 13
“In particular, psychedelics have recently received a tremendous increase in positive attention relative to other drugs, with therapeutic effects noted in clinical studies conducted with patients suffering from depression (18), anxiety (19), alcoholism (23), tobacco addiction (24) and obsessive–compulsive disorder (25).”
Background
Psychedelics, OCD and related disorders: A systematic review
Graziosi, M., Rohde, J. S., Tiwari, P., Siev, J., & Yaden, D. B. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100873 · Cited by 20
Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom ( Psilocybe cubensis ): A Systematic Review
Thaoboonruang, N., Lohitnavy, M., & Lohitnavy, O. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2399128 · Cited by 11
“…research is investigating the efficacy of psilocybin in addressing conditions such as obsessive-compulsive disorder (Moreno et al. 2006), alcohol addiction (Bogenschutz et al. 2015), tobacco addiction (Johnson et al. 2014, 2017) and posttraumatic stress disorder (PTSD) (Krediet et al. 2020).”
Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts
Wilson‐Poe, A. R., Hoffman, K. A., Pertl, K., Luoma, J., Bazinet, A. D., Stauffer, C. S., McCarty, D. W., & Korthuis, P. T. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2401982 · Cited by 11
“…(LSD), and other serotonergic psychedelics may induce enduring improvements in treatment-resistant depression, alcohol and tobacco use disorders, and posttraumatic stress disorder (PTSD) (Bogenschutz et al. 2022; Johnson et al. 2014; Perez et al. 2023; Sarmanlu et al. 2023; Wong et al. 2023).”
Beyond psychedelics: set and setting in general psychiatric practice
Kozak, Z., & Miller, C. W. T. (2024) · International Review of Psychiatry · doi:10.1080/09540261.2024.2419662 · Cited by 12
“…et al., 2016; Grob et al., 2011; Ross et al., 2016), post-traumatic stress disorder (PTSD) (Mitchell et al., 2021; Mithoefer et al., 2011), and substance use disorders (Bogenschutz et al., 2015; Johnson et al., 2014), the specific mechanisms underlying their therapeutic efficacy have been elusive.”
Acute Lysergic Acid Diethylamide Does Not Influence Reward-Driven Decision Making of C57BL/6 Mice in the Iowa Gambling Task
Elsilä, L. V., Korhonen, N., Hyytiä, P., & Korpi, E. R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.602770 · Cited by 11
“, 2016), addiction (Johnson et al., 2014; Bogenschutz et al., 2015), and anxiety-related disorders (Gasser et al.”
Background
The Association of Classic Serotonergic Psychedelic Use and Intention of Future Use with Nature Relatedness
Longo, M. S. C., Bienemann, B., Multedo, M., Negreiros, M. A., Schenberg, E. E., & Mograbi, D. C. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2112788 · Cited by 14
“…has also been shown effective in reducing depressive and anxious symptoms in terminal cancer patients (Griffiths et al. 2016) and tobacco cessation (Johnson et al. 2014) and in an open-label study has shown efficacy in obsessive-compulsive disorder (Moreno et al. 2006) and alcohol dependence…”
Background
The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada
Glynos, N. G., Kruger, D. J., Kolbman, N., Boehnke, K. F., & Lucas, P. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2242353 · Cited by 13
“Indeed, psilocybin-assisted therapy shows potential for treating major depressive disorder (Carhart-Harris et al. 2021; Davis et al. 2021; Goodwin et al. 2022), as well as alcohol (Bogenschutz et al. 2015, 2022) and tobacco dependence (Johnson et al. 2014; Johnson, Garcia-Romeu, and Griffiths 2016).”
Background
The possible place for psychedelics in pharmacotherapy of mental disorders
Wojtas, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00550-9 · Cited by 12
“When combined with Cognitive-Behavioral Therapy (CBT) for cessation of smoking, 80% of participants maintained abstinence at the 6-month follow-up, 67% at the 12-month follow-up, and 75% at the 2.5-year follow-up [141, 142].”
MethodInfluential
Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
Denis-Lalonde, D., & Estefan, A. (2020) · Journal of Mental Health and Addiction Nursing · doi:10.22374/jmhan.v4i1.40 · Cited by 11
“e8 Psilocybin and Tobacco Cessation In the first-ever study exploring the use of psychedelics as an adjunct to tobacco cessation treatment, 15 participants with an average of 6 previous attempts at quitting and 31 years as smokers underwent 2-3 psilocybin-assisted sessions as part of a 15-week treatment protocol.(48)…”
BackgroundMethod
Ayahuasca: Between Cognition and Culture
Peláez, I. E. A. (2020) · Publicacions URV eBooks · doi:10.17345/9788484248347 · Cited by 11
Psychedelic-Assisted Psychotherapy After COVID-19: The Therapeutic Uses of Psilocybin and MDMA for Pandemic-Related Mental Health Problems
Argento, E., Christie, D., Mackay, L., Callon, C., & Walsh, Z. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.716593 · Cited by 12
Experiences With Sacred Mushrooms and Psilocybin In Dialogue: Transdisciplinary Interpretations Of The “Velada”
Fagetti, A., & Mercadillo, R. E. (2022) · Anthropology of Consciousness · doi:10.1111/anoc.12163 · Cited by 12
Back to the future: A return to psychedelic treatment models for addiction
Hendricks, P. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550935 · Cited by 11
“This finding is even more impressive considering that Johnson et al. (2014) did not administer approved smoking-specific pharmacotherapies (i.e. nicotine replacement therapy, bupropion or varenicline), which are recommended as first-line treatments for tobacco dependence (Fiore et al., 2008).”
Background
Why Psychiatry Needs 3,4-Methylenedioxymethamphetamine: A Child Psychiatrist's Perspective
Sessa, B. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0531-1 · Cited by 13
Self-Care Practices with Psychedelics–A Qualitative Study of Users’ Perspectives
Soares, C. M., Leite, Â., & Pinto, M. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2071134 · Cited by 10
“…depression (CarhartHarris et al. 2016; Palhano-Fontes et al. 2018; Zarate et al. 2006); substance addictions (Bogenschutz et al. 2015; Johnson et al. 2014; Krupitsky et al. 2007); obsessivecompulsive disorder (Moreno et al. 2006); anxiety associated with life-threatening diseases…”
Background
Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests
Jones, G. M., Al‐Suwaidi, M., Castro‐Ramirez, F., McGuire, T. C., Mair, P., & Nock, M. K. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1169692 · Cited by 10
“, racial trauma (28–30), substance use disorders (31, 32), etc.”
Background
Therapeutic potential of psychedelics: History, advancements, and unexplored frontiers
Maia, J. M., de Oliveira, B. S. A., Branco, L. G. S., & Soriano, R. N. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.110951 · Cited by 11
Classic psychedelics and the treatment for alcoholism
Lodetti, G., de Bitencourt, R. M., & Rico, E. P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111129 · Cited by 11
Distinct 5-HT receptor subtypes regulate claustrum excitability by serotonin and the psychedelic, DOI
Anderson, T. L., Keady, J. V., Songrady, J. C., Tavakoli, N. S., Asadipooya, A., Neeley, R. E., Turner, J. R., & Ortinski, P. I. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102660 · Cited by 12
Psilocybin-assisted psychotherapy improves psychiatric symptoms across multiple dimensions in patients with cancer
Petridis, P. D., Grinband, J., Agin-Liebes, G., Kinslow, C. J., Zeifman, R. J., Bogenschutz, M. P., Griffiths, R. R., & Ross, S. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00331-0 · Cited by 10
“…clinical applications for which psilocybin is currently being investigated for, including major depressive disorder 25,26 , substance use disorders 27,28 , obsessive–compulsive disorder 29 , body dysmorphic disorder 30 and eating disorders 31 , we hypothesized that PAP would impart…”
Self-citation
A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 12
“Psilocybin has been shown to improve mood disorders, 24 – 33 smoking and drinking behavior in substance use disorders, 34 – 36 and increase well-being, 28,37 – 41 all with very few serious adverse events attributable to the psychedelic (but they can and do occur).”
Self-citation
The phenomenology of psilocybin: transformative insights for research and clinical practice
Metastasio, A., Prevete, E., Venturini, S., Garofalo, A., Cecconello, B., Pisapia, N. D., & Corazza, O. (2025) · Frontiers in Psychology · doi:10.3389/fpsyg.2025.1455902 · Cited by 14
The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression
Greenway, K. T., Garel, N., Dinh-Williams, L.-A., Lévesque, J. T., Kaelen, M., Dagenais‐Beaulé, V., de la Salle, S., Erritzøe, D., Looper, K. J., Turecki, G., et al. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2025.102 · Cited by 12
“Scores on the MEQ and EBI scales were of a comparable magnitude to those observed in trials of psilocybin-assisted psychotherapy, 25,34 – 36 despite the significant pharmacological differences between ketamine and psilocybin.”
Classic psychedelics as therapeutics for psychiatric disorders
Nichols, C. D., & Hendricks, P. S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00049-9 · Cited by 11
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
Higgins, G. A., & Sellers, E. M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.007 · Cited by 10
Effects of serotonergic psychedelics on mitochondria: Transdiagnostic implications for mitochondria-related pathologies
Fissler, P., Vandersmissen, A., Filippi, M., Mavioğlu, R. N., Scholkmann, F., Karabatsiakis, A., & Krähenmann, R. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231164707 · Cited by 10
“…diseases such as cancer (Gasser et al., 2015; Griffiths et al., 2016; Grob et al., 2011; Ross et al., 2016), substance use disorders (Bogenschutz et al., 2015; Garcia-Romeu et al., 2014; Johnson et al., 2014, 2017; Thomas et al., 2013), and obsessive-compulsive disorder (Moreno et al., 2006).”
Background
Effect of LSD and music on the time-varying brain dynamics
Adamska-Stolarczyk, I., & Finc, K. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06394-8 · Cited by 12
“…psychological distress (Gasser et al. 2015; Griffiths et al. 2016; Grob et al. 2011; Ross et al. 2016), addiction (Bogenschutz et al. 2015; Bogenschutz and Johnson 2016; Johnson et al. 2014), and post-traumatic stress disorder (Mithoefer et al. 2019; Ot’alora et al. 2018; Var-ker et al. 2021).”
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States
Herrmann, Z. M., Levin, A. W., Cole, S. P., Slabaugh, S., Barnett, B. S., Penn, A., Jain, R., Raison, C. L., Rajanna, B., & Jain, S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0030 · Cited by 11
Effects of psilocybin, the 5-HT2A receptor agonist TCB-2, and the 5-HT2A receptor antagonist M100907 on visual attention in male mice in the continuous performance test
Rahbarnia, A., Li, Z., & Fletcher, P. J. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06474-9 · Cited by 11
“…life-threatening cancer (Griffiths et al. 2016; Ross et al. 2016; Carhart-Harris et al. 2018; Davis et al. 2021), enhances the effectiveness of tobacco smoking cessation programs (Johnson et al. 2014), and reduces alcohol craving and use in people with alcohol dependence (Bogenschutz et al. 2015).”
From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff, J., Nunes, J. C., Costa, G. P. A., Sofuoglu, M., MacLean, R. R., & Aquino, J. P. D. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16045 · Cited by 12
Rational Suicide in the Elderly
Balasubramaniam, M., & McCue, R. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6 · Cited by 10
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder
Moerke, M. J., McMahon, L. R., & Wilkerson, J. L. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018028 · Cited by 11
“Furthermore, follow-up at 2.5 years revealed that 60% of the participants had remained abstinent (Johnson et al., 2017).”
BackgroundInfluential
Nicotine addiction: Translational insights from circuit neuroscience
Scarlata, M., Keeley, R. J., & Stein, E. A. (2021) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2021.173171 · Cited by 10
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 12
“In another study, 80% of long-term heavy tobacco smokers demonstrated abstinence from smoking 6 months after two psilocybin doses [120].”
Background
Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse
Majić, T., Jungaberle, H., Schmidt, T. T., Zeuch, A., Hermle, L., & Gallinat, J. (2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-103085 · Cited by 10
The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges
Scala, M., Fabbri, C., Fusar-Poli, P., Di Lorenzo, G., Ferrara, M., Amerio, A., Fusar-Poli, L., Pichiecchio, A., Asteggiano, C., Menchetti, M., et al. (2024) · CNS Spectrums · doi:10.1017/s1092852924002268 · Cited by 13
Hopelessness, Suicidality, and Co-Occurring Substance Use among Adolescent Hallucinogen Users—A National Survey Study
Desai, S. R., Jain, V., Xavier, S., & Du, W. (2022) · Children · doi:10.3390/children9121906 · Cited by 9
“disorder [10], reduction in Obsessive—Compulsive Disorder symptoms [11], and improvement in addictive behaviors [12,13].”
Background
The Role of Music in Psychedelic-Assisted Therapy: A Comparative Analysis of Neuroscientific Research, Indigenous Entheogenic Ritual, and Contemporary Care Models
Efthimiou, A. A., Cardinale, A. M., & Kepa, A. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2023.0058 · Cited by 11
“These sub-stances have been tested and used to treat a range of mental health symptoms and disorders, including depression, 11 obsessive compulsive disorder, 12 post-traumatic stress disorder (PTSD), 13 anxiety, 14 alcohol misuse, 15 nicotine addiction, 16 and cancer-related psychological distress.”
Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery
VanderZwaag, B., Garcia‐Romeu, A., & García-Barrera, M. A. (2024) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253241264812 · Cited by 10
Self-citation
Masking Influences: A Systematic Review of Placebo Control and Masking in Psychedelic Studies
Barstowe, A., & Kajonius, P. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2424272 · Cited by 9
“…studies have investigated the potential benefits of psychedelics for the treatment of various psychiatric illnesses such as nicotine dependence (Johnson et al. 2014), obsessive-compulsive disorder (Moreno et al. 2006), alcohol-use disorder (Bogenschutz et al. 2015), anxiety and depression…”
The psychedelic (−)-2,5-dimethoxy-4-iodoamphetamine [(−)-DOI] demonstrates efficacy in reducing cocaine reward and motivation in male rats
Salinsky, L. M., Merritt, C. R., Garcia, E. J., Fox, R. G., Zamora, J. C., Anastasio, N. C., & Cunningham, K. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06765-3 · Cited by 9
“An open-label pilot study of psilocybin in nicotine-dependent smokers in the context of psychosocial support demonstrated that 80% of participants achieved abstinence at 6-month follow-up which exceeds other nicotine cessation treatments (Johnson et al. 2014).”
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 9
An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically
Kruger, D. J., Glynos, N. G., Fields, C. W., Herberholz, M., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2142709 · Cited by 9
“A series of eight questions were developed to briefly assess basic knowledge of various topics surrounding psychedelics, such as legal status, active compounds, known therapeutic efficacy based on the clinical trial literature (Davis et al., 2021a; Johnson et al. 2014; Mitchell et al. 2021), side effects, and abuse po…”
Background
Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
Nicholas, C. R. N., Horton, D. M., Malicki, J., Baltes, A., Hutson, P. R., & Brown, R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0012 · Cited by 10
“11,12 Early data from population-based research suggest applications of PAT for SUD may extend to OUD, 13–15 and is further supported by an early controlled study of lysergic acid diethylamide for OUD.”
Psychedelics and fNIRS neuroimaging: exploring new opportunities
Scholkmann, F., & Vollenweider, F. X. (2022) · Neurophotonics · doi:10.1117/1.nph.10.1.013506 · Cited by 9
Assessing the effects of 5-HT2A and 5-HT5A receptor antagonists on DOI-induced head-twitch response in male rats using marker-less deep learning algorithms
Cyrano, E., & Popik, P. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00679-1 · Cited by 8
Emerging medications and pharmacological treatment approaches for substance use disorders
Raymond, J. S., Athanasopoulos, A. G., Badolato, C. J., Doolan, T. M., Scicluna, R. L., Everett, N. A., Bowen, M. T., & James, M. H. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173952 · Cited by 9
“Furthermore, an open-label pilot study using psilocybin-assisted psychotherapy to treat nicotine addiction found that 80% of participants were abstinent at the 6-month follow-up (Johnson et al., 2014) and 67% at 12 months (Johnson et al., 2017).”
The therapeutic effects of psychedelics for opioid use disorder: A systematic review of clinical studies
Weleff, J., Pulido-Saavedra, A., Aghaei, A. M., Ing, K., Arakelian, M. H., Fontenele, R., Nero, N., Barnett, B. S., Anand, A., Nia, A. B., et al. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116446 · Cited by 8
Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Hodge, A.-L., Forsyth, A., Noorani, T. N., Muthukumaraswamy, S. D., Rolleston, A. K., & McHugh, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00436 · Cited by 9
Psychedelics beyond medicine: Treatment, enhancement, hype, consent, and the limits of medicalization
Caraccio, M., Cheung, K., Mann, S. P., Bruce, L., Jacobs, E., Villiger, D., Sandbrink, J. D., Register, C., Hannikainen, I. R., Høeg, M. L., et al. (2025) · Philosophical Psychology · doi:10.1080/09515089.2025.2532761 · Cited by 8
“…treatments for a variety of mood and substance use disorders, including depression, anxiety, and alcohol use disorder (Goodwin et al., 2022; Johnson et al., 2014; Meling et al., 2024; Raison et al., 2023; Ross et al., 2016; Schimmers et al., 2022; Smith et al., 2022b; Sicignano et al.,…”
Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 10
A Virtual Clinical Trial of Psychedelics to Treat Patients With Disorders of Consciousness
Alnagger, N., Cardone, P., Martial, C., Perl, Y. S., Mindlin, I., Sitt, J. D., Roseman, L., Carhart-Harris, R. L., Nutt, D., Mallaroni, P., et al. (2025) · Advanced Science · doi:10.1002/advs.202511780 · Cited by 8
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
A Critical View on New and Future Antidepressants
Serretti, A. (2024) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1145 · Cited by 11
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Neurobiological Considerations for Tobacco Use Disorder
Chawla, M., & Garrison, K. A. (2018) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-018-0168-3 · Cited by 9
The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice
Stein, C. A., Penn, A., Hope, S., Dorsen, C. G., & Mangini, M. (2022) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13371 · Cited by 9
Psilocybin‐assisted psychotherapy for methamphetamine use disorder: A pilot open‐label safety and feasibility study.
Knock, E., Siefried, K. J., Bedi, G., Albert, S., Day, R. O., Ezard, N., Ross, M., Liknaitzky, P., & Brett, J. (2025) · Addiction · doi:10.1111/add.70187 · Cited by 9
Trait Openness and serotonin 2A receptors in healthy volunteers: A positron emission tomography study
Stenbæk, D. S., Kristiansen, S., Burmester, D., Madsen, M. K., Frokjaer, V. G., Knudsen, G. M., & Fisher, P. M. (2019) · Human Brain Mapping · doi:10.1002/hbm.24511 · Cited by 11
“…al., 2016) and is known to induce highly meaningful and, occasionally, mystical-type experiences (Baumeister, Barnes, Giaroli, & Tracy, 2014; Griffiths et al., 2011; Griffiths et al., 2016; Griffiths, Richards, McCann, & Jesse, 2006; Johnson et al., 2014; MacLean et al., 2011; Ross et al., 2016).”
Background
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Spangemacher, M., Mertens, L. J., Färber, L. V., Jungaberle, A., Jungaberle, H., & Gründer, G. (2024) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0224 · Cited by 7
Naturalistic Psychedelic Use and Psychotic Symptoms: A Cross-Sectional Study of Individuals with a Personal or Family History of Psychotic or Bipolar Disorders
Dourron, H. M., Bradley, M., Simonsson, O., Copes, H., Grossman, D., Shallcross, R. A., & Hendricks, P. S. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0036 · Cited by 7
Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans
Thaoboonruang, N., Lohitnavy, O., Ya, K., & Lohitnavy, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-98202-w · Cited by 8
“Plasma psilocin concentrations were measured at 5, 10, 20, 30, 45, 60, 90, 120, 180-, 240-, 360-, and 420-min post-dose.”
The therapeutic potential of psilocybin beyond psychedelia through shared mechanisms with ketamine
Park, D., Lee, G., Lee, W.-G., Kim, B. S., Lee, Y., & Kim, J. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03100-2 · Cited by 11
“Since then, psilocybin has shown therapeutic potential for a range of psychiatric conditions, including MDD [9, 10], obsessive-compulsive disorder [31], and substance use disorders [32, 33].”
Exploring the therapeutic potential of psychedelics in treating substance use disorders
Li, Y., Li, H., Wang, H., & Wang, X. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03168-w · Cited by 6
“…session, combined with cognitive-behavioral therapy, can lead to long-term abstinence in a signi ﬁ cant proportion of participants, with an impressive 80% abstinence rate observed six months after treatment-far surpassing traditional smoking cessation methods (Table 1, Psilocybin) [35, 63].”
Psychedelics as pharmacotherapeutics for substance use disorders: A scoping review on clinical trials and perspectives on underlying neurobiology
Wittenkeller, L. M., Gudelsky, G. A., Winhusen, T. M., & Amato, D. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70181 · Cited by 7
“Two foundational open-label studies highlight the potential for psychedelic interventions to be used for SUDs (Bogenschutz et al., 2015; Johnson et al., 2014).”
Landscape analysis of pre-registered clinical trials involving classical psychedelics
Uyar, A., Forbrich, L., Lueken, U., & Evens, R. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251371690 · Cited by 6
“…psychedelics among healthy participants (Carhart-Harris et al., 2012; Griffiths et al., 2006), and later in conditions such as nicotine dependence (Johnson et al., 2014), anxiety and depression in patients with life-threatening illnesses (Ross et al., 2016), or depression (Carhart-Harris et al.,…”
Use of the head-twitch response to investigate the structure–activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines
Halberstadt, A. L., Luethi, D., Hoener, M. C., Trachsel, D., Brandt, S. D., & Liechti, M. E. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06279-2 · Cited by 8
“…promising results have been reported in clinical trials evaluating psilocybin for depression (Carhart-Harris et al. 2021; Davis et al. 2021), existential distress (Griffiths et al. 2016; Ross et al. 2016), nicotine dependence (Johnson et al. 2014, 2017), and alcoholism (Bogenschutz et al. 2015).”
A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Brandt, J. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231170340 · Cited by 9
“…anxiety, obsessive – compulsive disorder, alcohol dependence, tobacco dependence, and end-of-life “ existential ” palliative care (Bogenschutz et al., 2015; Carhart-Harris et al., 2016; Grif ﬁ ths et al., 2016; Grob et al., 2011; Johnson et al., 2014; Moreno et al., 2006; Ross et al., 2016).”
Background
Psychedelics, With a Focus on Psilocybin: Issues for the Clinician
Garakani, A., Alexander, J. L., Sumner, C. R., Pine, J. H., Gross, L. S., Raison, C. L., Aaronson, S. T., & Baron, D. A. (2023) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000729 · Cited by 7
The Psychedelic N , N -Dipropyltryptamine Prevents Seizures in a Mouse Model of Fragile X Syndrome via a Mechanism that Appears Independent of Serotonin and Sigma1 Receptors
Tyagi, R., Saraf, T. S., & Canal, C. E. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.3c00137 · Cited by 7
Psychedelic-assisted therapy for people with gambling disorder?
Romero, P., Czakó, A., van den Brink, W., & Demetrovics, Z. (2024) · Journal of Behavioral Addictions · doi:10.1556/2006.2024.00004 · Cited by 10
Psychedelics and substance use disorder treatment
DuPont, C. M., & Johnson, M. W. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.005 · Cited by 8
Self-citation
In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates
Prabhakaran, J., DeLorenzo, C., Zanderigo, F., Knudsen, G. M., Gilling, N., Pratap, M., Jorgensen, M. J., Daunais, J., Kaplan, J. R., Parsey, R. V., et al. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30329 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
Kinderlehrer, D. A. (2023) · International Medical Case Reports Journal · doi:10.2147/imcrj.s395342 · Cited by 7
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 9
Psychedelics – Re-opening the doors of perception
Heal, D. J., Henningfield, J. E., Frenguelli, B. G., Nutt, D., & Smith, S. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.08.024 · Cited by 7
Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
de Sousa, T. R., Rema, J., Machado, S. E. D. C., & Novais, F. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201145800 · Cited by 7
Utilisation des psychédéliques en psychiatrie : lien avec les neurotrophines
Corne, R., & Mongeau, R. (2019) · Biologie Aujourd hui · doi:10.1051/jbio/2019015 · Cited by 8
Altered trajectories in the dynamical repertoire of functional network states under psilocybinPreprint
Lord, L.-D., Expert, P., Atasoy, S., Roseman, L., Rapuano, K. M., Lambiotte, R., Nutt, D. J., Deco, G., Carhart-Harris, R. L., Kringelbach, M. L., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/376491 · Cited by 7
“Investigating the link between the brain’s dynamical repertoire and departures from normal waking consciousness may help better understand functional mechanisms underlying the therapeutic potential of psilocybin for disorders including depression, anxiety and addiction (18-21).”
Background
Exploring factors associated with the intensity of a mystical experience following naturalistic psychedelic use: A retrospective survey
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111300 · Cited by 7
Exploring the Frontiers of Psychedelics: A New Chromatographic Method for Detection and Quantification of Psilocybin and Psilocin in Psilocybe cubensis Mushrooms
Galdino, T. P., de Oliveira, L. C., da Luz, M. A., Barbosa, R. C., Torres, M. D. C. D. M., Sivieri, K., Fernandes, P. A., dos Santos, M. L., de Lima, A. G. B., Silva, S. M. D. L., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c02751 · Cited by 6
H 2 O 2 ‐Activated Serotonin Precursor Probe for Mapping Neuronal Redox Homeostasis Reveals 5‐HT Interactions with Neighboring Proteins Under Oxidative Stress
Liu, Y., Yuan, J., Zhang, T., Cai, X., Xu, M., Wang, X., Wang, R. Y., Zhang, B., Zhu, H., & Qian, Y. (2025) · Advanced Science · doi:10.1002/advs.202502360 · Cited by 6
Is music a drug? How music listening may trigger neurochemical responses in the brain
Reybrouck, M., & Dyck, E. V. (2024) · Musicae Scientiae · doi:10.1177/10298649241236770 · Cited by 17
“…demonstrating that music can facilitate peak experiences (Griffiths et al., 2006), sustained positive behavioral changes (Griffiths et al., 2011) and personality adaptations (MacLean et al., 2011), and constructive clinical outcomes (Griffiths et al., 2016; Johnson et al., 2014; Ross et al., 2016).”
Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2375720 · Cited by 6
“…common predictor of beneficial mental health outcomes, with significant correlations between measures of the mystical experience and smoking cessation (Johnson et al. 2014; Romeo et al. 2023), or reduced alcohol use (Bogenschutz et al. 2015; Garcia-Romeu et al. 2019; Kervadec et al. 2023).”

Authors: Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R.
Affiliations: Johns Hopkins University (US)
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA
ORCID: Johnson, Matthew W
Griffiths, Roland R
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2014-09-11
Volume: 28
Issue: 11
Pages: 983-992
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881114548296
PMC: PMC4286320
OpenAlex: W2122459973
Cited by: 914
References: 63
Citations by year: 2026: 71 · 2025: 130 · 2024: 126 · 2023: 112 · 2022: 121 · 2021: 94 · 2020: 70 · 2019: 33 · 2018: 48 · 2017: 45 · 2016: 46 · 2015: 13 · 2014: 3
FWCI: 41.88
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: World Health Organization
National Institute on Drug Abuse (R01DA003889, T32DA007209)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Keywords: psilocybin, tobacco dependence, smoking cessation, nicotine dependence, hallucinogens, 5-HT2A receptor agonists, adjunctive therapy, abstinence, treatment safety and feasibility
MeSH terms: Attitude, Carbon Monoxide, Combined Modality Therapy, Cotinine, Dose-Response Relationship, Drug, Female, Humans, Male, Middle Aged, Pilot Projects, Psilocybin, Tobacco Use Disorder, Biomarkers, Cognitive Behavioral Therapy, Smoking Cessation, Behavior, Addictive, Treatment Outcome, Serotonin Receptor Agonists, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks